| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tuberculosis | 76 | 2023 | 566 | 12.310 |
Why?
|
| Mycobacterium tuberculosis | 79 | 2023 | 455 | 10.490 |
Why?
|
| Interferon-gamma Release Tests | 13 | 2019 | 85 | 4.090 |
Why?
|
| Tuberculosis, Pulmonary | 27 | 2021 | 248 | 4.010 |
Why?
|
| Antitubercular Agents | 27 | 2023 | 341 | 3.540 |
Why?
|
| Kidney Transplantation | 25 | 2024 | 622 | 2.800 |
Why?
|
| Bacterial Proteins | 27 | 2017 | 872 | 2.750 |
Why?
|
| Texas | 68 | 2024 | 3521 | 2.450 |
Why?
|
| Latent Tuberculosis | 11 | 2019 | 83 | 2.370 |
Why?
|
| Middle Aged | 147 | 2025 | 25388 | 2.070 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 12 | 2023 | 143 | 1.980 |
Why?
|
| Population Surveillance | 12 | 2019 | 380 | 1.890 |
Why?
|
| Interferon-gamma | 12 | 2018 | 508 | 1.870 |
Why?
|
| HIV Infections | 26 | 2021 | 1863 | 1.870 |
Why?
|
| Adult | 141 | 2024 | 28623 | 1.860 |
Why?
|
| Male | 186 | 2025 | 59138 | 1.700 |
Why?
|
| Humans | 297 | 2025 | 121743 | 1.680 |
Why?
|
| Antigens, Bacterial | 11 | 2018 | 312 | 1.660 |
Why?
|
| Drug Resistance, Bacterial | 12 | 2018 | 358 | 1.630 |
Why?
|
| Female | 189 | 2025 | 64492 | 1.620 |
Why?
|
| Liver Transplantation | 13 | 2024 | 1030 | 1.610 |
Why?
|
| Coinfection | 7 | 2019 | 170 | 1.590 |
Why?
|
| Aged | 90 | 2025 | 18464 | 1.480 |
Why?
|
| Baths | 3 | 2020 | 16 | 1.450 |
Why?
|
| Tuberculin Test | 14 | 2019 | 131 | 1.420 |
Why?
|
| Cross Infection | 7 | 2020 | 331 | 1.400 |
Why?
|
| Anti-Infective Agents, Local | 3 | 2020 | 70 | 1.380 |
Why?
|
| Health Personnel | 7 | 2019 | 500 | 1.350 |
Why?
|
| Predictive Value of Tests | 22 | 2024 | 2059 | 1.340 |
Why?
|
| Aortic Valve Insufficiency | 7 | 2025 | 138 | 1.330 |
Why?
|
| Magnetic Resonance Imaging, Cine | 10 | 2025 | 146 | 1.300 |
Why?
|
| Retrospective Studies | 81 | 2025 | 15601 | 1.260 |
Why?
|
| Health Status Disparities | 3 | 2020 | 213 | 1.240 |
Why?
|
| Risk Factors | 55 | 2024 | 9677 | 1.210 |
Why?
|
| Enzyme-Linked Immunospot Assay | 3 | 2016 | 12 | 1.210 |
Why?
|
| Mass Screening | 9 | 2019 | 776 | 1.200 |
Why?
|
| Prognosis | 31 | 2025 | 4477 | 1.150 |
Why?
|
| Polymorphism, Genetic | 9 | 2009 | 804 | 1.150 |
Why?
|
| Graft Rejection | 13 | 2024 | 577 | 1.130 |
Why?
|
| Molecular Epidemiology | 14 | 2017 | 157 | 1.060 |
Why?
|
| Hernia, Hiatal | 6 | 2021 | 53 | 1.020 |
Why?
|
| Laparoscopy | 11 | 2024 | 498 | 1.010 |
Why?
|
| AIDS-Related Opportunistic Infections | 11 | 2011 | 138 | 0.990 |
Why?
|
| Graft Survival | 13 | 2024 | 520 | 0.930 |
Why?
|
| Mitral Valve Insufficiency | 5 | 2024 | 155 | 0.930 |
Why?
|
| Living Donors | 8 | 2024 | 110 | 0.920 |
Why?
|
| Tissue Donors | 6 | 2024 | 496 | 0.910 |
Why?
|
| Young Adult | 39 | 2022 | 8712 | 0.910 |
Why?
|
| Sputum | 12 | 2018 | 111 | 0.910 |
Why?
|
| Chlorhexidine | 3 | 2020 | 46 | 0.910 |
Why?
|
| Organ Transplantation | 2 | 2022 | 163 | 0.890 |
Why?
|
| Prevalence | 18 | 2019 | 2370 | 0.860 |
Why?
|
| Catalase | 4 | 2013 | 50 | 0.840 |
Why?
|
| Genotype | 24 | 2019 | 2533 | 0.840 |
Why?
|
| Heart Transplantation | 7 | 2024 | 856 | 0.830 |
Why?
|
| Diabetes Mellitus | 3 | 2020 | 840 | 0.820 |
Why?
|
| Adolescent | 47 | 2021 | 18879 | 0.820 |
Why?
|
| Mycobacterium Infections | 4 | 2009 | 31 | 0.810 |
Why?
|
| Phlebotomy | 2 | 2019 | 17 | 0.810 |
Why?
|
| Biomedical Research | 2 | 2019 | 507 | 0.810 |
Why?
|
| Tissue and Organ Procurement | 4 | 2024 | 218 | 0.790 |
Why?
|
| Logistic Models | 19 | 2018 | 1756 | 0.790 |
Why?
|
| Patient Readmission | 3 | 2021 | 363 | 0.790 |
Why?
|
| Bacterial Typing Techniques | 11 | 2013 | 100 | 0.770 |
Why?
|
| Hospitals, Public | 1 | 2021 | 38 | 0.770 |
Why?
|
| Isoniazid | 6 | 2017 | 69 | 0.770 |
Why?
|
| Pancreas Transplantation | 5 | 2024 | 36 | 0.750 |
Why?
|
| Rifampin | 6 | 2021 | 142 | 0.740 |
Why?
|
| Genetic Predisposition to Disease | 11 | 2011 | 3066 | 0.720 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2019 | 813 | 0.710 |
Why?
|
| DNA, Bacterial | 14 | 2015 | 480 | 0.710 |
Why?
|
| Heart-Assist Devices | 7 | 2024 | 1022 | 0.710 |
Why?
|
| Postoperative Complications | 16 | 2024 | 2868 | 0.710 |
Why?
|
| Brain Death | 2 | 2021 | 55 | 0.700 |
Why?
|
| Transplant Recipients | 8 | 2022 | 210 | 0.690 |
Why?
|
| Lung Transplantation | 6 | 2024 | 315 | 0.680 |
Why?
|
| Hospitals, High-Volume | 1 | 2019 | 32 | 0.670 |
Why?
|
| Vascular Patency | 1 | 2020 | 153 | 0.670 |
Why?
|
| Foreign Professional Personnel | 1 | 2019 | 2 | 0.670 |
Why?
|
| Tuberculosis Vaccines | 1 | 2019 | 16 | 0.660 |
Why?
|
| Contact Tracing | 5 | 2018 | 56 | 0.660 |
Why?
|
| Case-Control Studies | 21 | 2021 | 3221 | 0.650 |
Why?
|
| United States | 28 | 2024 | 10415 | 0.640 |
Why?
|
| Disease Eradication | 1 | 2019 | 34 | 0.640 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2020 | 93 | 0.640 |
Why?
|
| Biological Assay | 2 | 2019 | 101 | 0.640 |
Why?
|
| General Surgery | 4 | 2021 | 201 | 0.640 |
Why?
|
| Tuberculosis, Meningeal | 1 | 2019 | 28 | 0.640 |
Why?
|
| Drug Utilization | 1 | 2020 | 157 | 0.640 |
Why?
|
| Blood Specimen Collection | 1 | 2019 | 46 | 0.640 |
Why?
|
| Angioplasty, Balloon | 1 | 2020 | 143 | 0.630 |
Why?
|
| Vascular Diseases | 1 | 2020 | 144 | 0.620 |
Why?
|
| Anti-Bacterial Agents | 7 | 2020 | 2378 | 0.610 |
Why?
|
| Radiography, Thoracic | 3 | 2016 | 151 | 0.600 |
Why?
|
| Incidence | 20 | 2024 | 2992 | 0.600 |
Why?
|
| Treatment Outcome | 37 | 2024 | 11685 | 0.590 |
Why?
|
| Pain Management | 1 | 2019 | 166 | 0.590 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 215 | 0.590 |
Why?
|
| Kidney Failure, Chronic | 7 | 2024 | 856 | 0.590 |
Why?
|
| Odds Ratio | 9 | 2020 | 1226 | 0.580 |
Why?
|
| Sensitivity and Specificity | 19 | 2021 | 2007 | 0.580 |
Why?
|
| Substance-Related Disorders | 4 | 2019 | 450 | 0.570 |
Why?
|
| Critical Care | 2 | 2020 | 643 | 0.570 |
Why?
|
| Antibiotics, Antitubercular | 4 | 2021 | 34 | 0.560 |
Why?
|
| Residence Characteristics | 1 | 2019 | 265 | 0.560 |
Why?
|
| Immunoenzyme Techniques | 2 | 2007 | 268 | 0.560 |
Why?
|
| Cardiomyopathies | 4 | 2024 | 476 | 0.560 |
Why?
|
| Automation, Laboratory | 1 | 2016 | 12 | 0.560 |
Why?
|
| Heart Failure | 9 | 2024 | 2121 | 0.540 |
Why?
|
| Time Factors | 16 | 2022 | 5995 | 0.540 |
Why?
|
| Pain, Postoperative | 1 | 2019 | 252 | 0.540 |
Why?
|
| Reproducibility of Results | 10 | 2024 | 2792 | 0.540 |
Why?
|
| Heart Neoplasms | 3 | 2022 | 102 | 0.530 |
Why?
|
| Child, Preschool | 27 | 2019 | 13771 | 0.530 |
Why?
|
| Prospective Studies | 24 | 2024 | 5906 | 0.520 |
Why?
|
| Comorbidity | 9 | 2021 | 1473 | 0.520 |
Why?
|
| Macrophages | 7 | 2022 | 614 | 0.510 |
Why?
|
| Streptococcus pyogenes | 8 | 2008 | 74 | 0.510 |
Why?
|
| Infant | 21 | 2023 | 12289 | 0.500 |
Why?
|
| Cross-Sectional Studies | 13 | 2021 | 3286 | 0.500 |
Why?
|
| Intensive Care Units | 4 | 2021 | 473 | 0.500 |
Why?
|
| Microbial Sensitivity Tests | 16 | 2017 | 793 | 0.500 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 395 | 0.490 |
Why?
|
| Cluster Analysis | 11 | 2017 | 386 | 0.490 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2011 | 2576 | 0.490 |
Why?
|
| Risk Assessment | 9 | 2024 | 3222 | 0.490 |
Why?
|
| Aged, 80 and over | 27 | 2022 | 6098 | 0.480 |
Why?
|
| Child | 37 | 2021 | 24035 | 0.480 |
Why?
|
| Urban Population | 4 | 2013 | 216 | 0.480 |
Why?
|
| Multivariate Analysis | 11 | 2019 | 1395 | 0.480 |
Why?
|
| Clostridium Infections | 1 | 2018 | 230 | 0.480 |
Why?
|
| Polyomavirus Infections | 4 | 2024 | 88 | 0.480 |
Why?
|
| BCG Vaccine | 4 | 2018 | 114 | 0.470 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 6 | 2017 | 148 | 0.470 |
Why?
|
| Prisoners | 3 | 2009 | 33 | 0.470 |
Why?
|
| Fibrosis | 8 | 2024 | 422 | 0.470 |
Why?
|
| Proportional Hazards Models | 12 | 2021 | 1284 | 0.460 |
Why?
|
| Disease Outbreaks | 5 | 2017 | 318 | 0.460 |
Why?
|
| ROC Curve | 4 | 2024 | 550 | 0.460 |
Why?
|
| Ventricular Dysfunction, Right | 2 | 2025 | 78 | 0.460 |
Why?
|
| Follow-Up Studies | 20 | 2024 | 4987 | 0.450 |
Why?
|
| Feces | 3 | 2018 | 692 | 0.450 |
Why?
|
| Ambulatory Care Facilities | 1 | 2016 | 228 | 0.440 |
Why?
|
| Renal Dialysis | 2 | 2020 | 834 | 0.440 |
Why?
|
| Vietnam | 4 | 2019 | 44 | 0.440 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 4 | 2016 | 33 | 0.430 |
Why?
|
| Fundoplication | 7 | 2024 | 65 | 0.430 |
Why?
|
| Bacteremia | 4 | 2013 | 405 | 0.430 |
Why?
|
| Robotic Surgical Procedures | 3 | 2024 | 197 | 0.420 |
Why?
|
| Tuberculosis, Lymph Node | 3 | 2019 | 23 | 0.420 |
Why?
|
| DNA Transposable Elements | 8 | 2006 | 179 | 0.420 |
Why?
|
| Glomerular Filtration Rate | 8 | 2024 | 470 | 0.420 |
Why?
|
| Polymorphism, Restriction Fragment Length | 12 | 2015 | 142 | 0.400 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2024 | 952 | 0.400 |
Why?
|
| Mycobacterium | 4 | 2007 | 29 | 0.400 |
Why?
|
| Motor Vehicles | 1 | 2011 | 9 | 0.400 |
Why?
|
| Urban Health Services | 1 | 2011 | 22 | 0.390 |
Why?
|
| Isoantibodies | 4 | 2024 | 72 | 0.390 |
Why?
|
| Internship and Residency | 5 | 2021 | 1149 | 0.390 |
Why?
|
| Mycobacterium bovis | 3 | 2019 | 35 | 0.380 |
Why?
|
| Aza Compounds | 1 | 2011 | 15 | 0.380 |
Why?
|
| Staphylococcal Infections | 4 | 2012 | 550 | 0.370 |
Why?
|
| Immunosuppressive Agents | 6 | 2020 | 645 | 0.370 |
Why?
|
| Renal Insufficiency | 3 | 2022 | 231 | 0.360 |
Why?
|
| Heller Myotomy | 2 | 2021 | 7 | 0.360 |
Why?
|
| Quinolines | 1 | 2011 | 95 | 0.360 |
Why?
|
| Liver Neoplasms | 4 | 2024 | 1379 | 0.360 |
Why?
|
| Infant, Newborn | 7 | 2022 | 8088 | 0.360 |
Why?
|
| Staphylococcus aureus | 5 | 2005 | 458 | 0.360 |
Why?
|
| Obesity | 4 | 2022 | 2082 | 0.350 |
Why?
|
| DNA Gyrase | 2 | 2009 | 21 | 0.350 |
Why?
|
| Drug Users | 1 | 2009 | 8 | 0.350 |
Why?
|
| Esophageal Achalasia | 2 | 2021 | 36 | 0.350 |
Why?
|
| China | 11 | 2019 | 227 | 0.340 |
Why?
|
| Observer Variation | 2 | 2024 | 297 | 0.340 |
Why?
|
| Geographic Information Systems | 3 | 2017 | 39 | 0.340 |
Why?
|
| Immunologic Tests | 2 | 2007 | 23 | 0.340 |
Why?
|
| Learning | 3 | 2022 | 357 | 0.330 |
Why?
|
| Sarcoma | 2 | 2022 | 197 | 0.330 |
Why?
|
| Soaps | 2 | 2020 | 8 | 0.330 |
Why?
|
| Cation Transport Proteins | 3 | 2007 | 99 | 0.330 |
Why?
|
| Antiretroviral Therapy, Highly Active | 7 | 2010 | 268 | 0.330 |
Why?
|
| Age Factors | 6 | 2020 | 2769 | 0.320 |
Why?
|
| BK Virus | 3 | 2019 | 58 | 0.320 |
Why?
|
| Bile Duct Neoplasms | 2 | 2021 | 112 | 0.320 |
Why?
|
| Cholangiocarcinoma | 2 | 2021 | 110 | 0.320 |
Why?
|
| Metabolic Syndrome | 2 | 2024 | 322 | 0.320 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2024 | 1199 | 0.320 |
Why?
|
| Viremia | 3 | 2019 | 128 | 0.310 |
Why?
|
| Cholecalciferol | 2 | 2019 | 22 | 0.310 |
Why?
|
| Nod2 Signaling Adaptor Protein | 1 | 2008 | 22 | 0.310 |
Why?
|
| Nephrectomy | 4 | 2021 | 169 | 0.310 |
Why?
|
| CD4 Lymphocyte Count | 9 | 2019 | 231 | 0.310 |
Why?
|
| Antilymphocyte Serum | 2 | 2020 | 57 | 0.310 |
Why?
|
| Ventricular Function, Left | 5 | 2023 | 500 | 0.310 |
Why?
|
| Patient Selection | 3 | 2021 | 648 | 0.310 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2022 | 339 | 0.310 |
Why?
|
| Tumor Virus Infections | 3 | 2019 | 135 | 0.310 |
Why?
|
| Microscopy, Fluorescence | 3 | 2016 | 330 | 0.300 |
Why?
|
| Surveys and Questionnaires | 13 | 2020 | 3619 | 0.300 |
Why?
|
| Linkage Disequilibrium | 4 | 2005 | 305 | 0.300 |
Why?
|
| Alcohol Drinking | 3 | 2019 | 336 | 0.300 |
Why?
|
| Mutation | 11 | 2018 | 5749 | 0.300 |
Why?
|
| Tuberculosis, Central Nervous System | 1 | 2007 | 11 | 0.300 |
Why?
|
| Fever | 3 | 2018 | 295 | 0.300 |
Why?
|
| Lung Neoplasms | 3 | 2022 | 1615 | 0.300 |
Why?
|
| Mycobacterium smegmatis | 2 | 2017 | 7 | 0.290 |
Why?
|
| Minisatellite Repeats | 3 | 2017 | 43 | 0.290 |
Why?
|
| Methicillin Resistance | 2 | 2004 | 117 | 0.290 |
Why?
|
| Heart Diseases | 2 | 2023 | 480 | 0.290 |
Why?
|
| Enterotoxins | 1 | 2007 | 83 | 0.280 |
Why?
|
| Kidney | 6 | 2024 | 1323 | 0.280 |
Why?
|
| Stroke Volume | 6 | 2024 | 446 | 0.280 |
Why?
|
| Databases, Factual | 4 | 2019 | 1138 | 0.280 |
Why?
|
| Interdisciplinary Communication | 2 | 2019 | 134 | 0.280 |
Why?
|
| Immunoglobulin G | 5 | 2022 | 774 | 0.280 |
Why?
|
| Myocardium | 3 | 2021 | 982 | 0.280 |
Why?
|
| Mortality | 3 | 2020 | 221 | 0.280 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2018 | 146 | 0.270 |
Why?
|
| HIV-1 | 3 | 2020 | 471 | 0.270 |
Why?
|
| Water Supply | 2 | 2004 | 25 | 0.270 |
Why?
|
| Thrombosis | 2 | 2022 | 505 | 0.270 |
Why?
|
| Obesity, Morbid | 3 | 2022 | 180 | 0.270 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 3 | 2010 | 24 | 0.270 |
Why?
|
| Bacterial Toxins | 1 | 2007 | 176 | 0.270 |
Why?
|
| Tuberculosis, Pleural | 1 | 2006 | 10 | 0.260 |
Why?
|
| Ventricular Remodeling | 5 | 2024 | 175 | 0.260 |
Why?
|
| Hypertension | 4 | 2021 | 1264 | 0.260 |
Why?
|
| Fluorescent Dyes | 2 | 2019 | 261 | 0.260 |
Why?
|
| Donor Selection | 3 | 2024 | 52 | 0.260 |
Why?
|
| Survival Rate | 8 | 2022 | 1983 | 0.260 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2024 | 365 | 0.250 |
Why?
|
| Registries | 4 | 2025 | 1351 | 0.250 |
Why?
|
| Interleukin-12 | 2 | 2017 | 118 | 0.250 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2024 | 220 | 0.250 |
Why?
|
| Herniorrhaphy | 3 | 2021 | 80 | 0.250 |
Why?
|
| Weaning | 2 | 2021 | 40 | 0.240 |
Why?
|
| Mutation, Missense | 1 | 2009 | 834 | 0.240 |
Why?
|
| Immunoassay | 2 | 2017 | 128 | 0.240 |
Why?
|
| Research Design | 2 | 2019 | 643 | 0.240 |
Why?
|
| Lung Diseases | 2 | 2019 | 378 | 0.240 |
Why?
|
| Emigration and Immigration | 3 | 2005 | 80 | 0.240 |
Why?
|
| Neurocysticercosis | 3 | 2011 | 21 | 0.240 |
Why?
|
| Cohort Studies | 11 | 2022 | 4635 | 0.230 |
Why?
|
| HLA Antigens | 4 | 2024 | 243 | 0.230 |
Why?
|
| Kidney Function Tests | 3 | 2024 | 127 | 0.230 |
Why?
|
| Genes, Bacterial | 2 | 2004 | 207 | 0.230 |
Why?
|
| DNA-Directed RNA Polymerases | 4 | 2010 | 113 | 0.230 |
Why?
|
| Mannose-Binding Lectin | 1 | 2004 | 5 | 0.230 |
Why?
|
| Area Under Curve | 3 | 2022 | 305 | 0.230 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2024 | 72 | 0.230 |
Why?
|
| Emigrants and Immigrants | 3 | 2015 | 147 | 0.230 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 2 | 2016 | 59 | 0.230 |
Why?
|
| Plasma Cells | 1 | 2024 | 47 | 0.230 |
Why?
|
| Chi-Square Distribution | 5 | 2013 | 570 | 0.230 |
Why?
|
| HIV Seronegativity | 1 | 2003 | 25 | 0.220 |
Why?
|
| Hyperinsulinism | 1 | 2024 | 67 | 0.220 |
Why?
|
| Socioeconomic Factors | 5 | 2011 | 857 | 0.220 |
Why?
|
| Esophageal Fistula | 1 | 2023 | 14 | 0.220 |
Why?
|
| Recurrence | 6 | 2018 | 1393 | 0.220 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2020 | 470 | 0.220 |
Why?
|
| Cicatrix | 2 | 2023 | 124 | 0.210 |
Why?
|
| Interspersed Repetitive Sequences | 2 | 2017 | 26 | 0.210 |
Why?
|
| Islets of Langerhans | 1 | 2024 | 174 | 0.210 |
Why?
|
| Tacrolimus | 2 | 2020 | 96 | 0.210 |
Why?
|
| Tricuspid Valve Insufficiency | 2 | 2020 | 63 | 0.210 |
Why?
|
| 3' Untranslated Regions | 1 | 2003 | 166 | 0.210 |
Why?
|
| Water Microbiology | 1 | 2002 | 23 | 0.210 |
Why?
|
| Mupirocin | 1 | 2002 | 19 | 0.210 |
Why?
|
| Neoadjuvant Therapy | 3 | 2021 | 328 | 0.210 |
Why?
|
| Atrial Fibrillation | 2 | 2023 | 622 | 0.210 |
Why?
|
| Faculty | 1 | 2023 | 100 | 0.210 |
Why?
|
| Alleles | 7 | 2011 | 1594 | 0.210 |
Why?
|
| Insulin-Secreting Cells | 1 | 2024 | 143 | 0.200 |
Why?
|
| Sequence Analysis, DNA | 8 | 2011 | 1758 | 0.200 |
Why?
|
| Interleukin-8 | 1 | 2003 | 210 | 0.200 |
Why?
|
| Surgical Wound Infection | 2 | 2016 | 256 | 0.200 |
Why?
|
| Sickle Cell Trait | 1 | 2022 | 11 | 0.200 |
Why?
|
| Waiting Lists | 2 | 2024 | 218 | 0.200 |
Why?
|
| Extracellular Matrix | 2 | 2020 | 230 | 0.200 |
Why?
|
| Carcinoid Tumor | 1 | 2022 | 21 | 0.200 |
Why?
|
| End Stage Liver Disease | 2 | 2024 | 178 | 0.200 |
Why?
|
| Solanum tuberosum | 1 | 2022 | 15 | 0.200 |
Why?
|
| Referral and Consultation | 2 | 2024 | 524 | 0.200 |
Why?
|
| Cryptococcosis | 5 | 2003 | 42 | 0.200 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2022 | 34 | 0.200 |
Why?
|
| Extracellular Vesicles | 1 | 2022 | 45 | 0.200 |
Why?
|
| Bacteriological Techniques | 3 | 2017 | 90 | 0.200 |
Why?
|
| Virulence | 8 | 2013 | 259 | 0.200 |
Why?
|
| Aminopeptidases | 2 | 2023 | 19 | 0.200 |
Why?
|
| Agammaglobulinemia | 1 | 2022 | 39 | 0.200 |
Why?
|
| Factor Xa Inhibitors | 1 | 2022 | 63 | 0.200 |
Why?
|
| Postprandial Period | 1 | 2022 | 75 | 0.190 |
Why?
|
| Fibromuscular Dysplasia | 1 | 2021 | 5 | 0.190 |
Why?
|
| Hemangiosarcoma | 1 | 2022 | 40 | 0.190 |
Why?
|
| Severity of Illness Index | 4 | 2021 | 2794 | 0.190 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2002 | 114 | 0.190 |
Why?
|
| Virtual Reality | 1 | 2021 | 27 | 0.190 |
Why?
|
| Algorithms | 4 | 2024 | 1573 | 0.190 |
Why?
|
| Weight Gain | 2 | 2024 | 383 | 0.190 |
Why?
|
| Respiratory Insufficiency | 2 | 2021 | 234 | 0.190 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2020 | 973 | 0.190 |
Why?
|
| Hemorrhage | 2 | 2022 | 457 | 0.190 |
Why?
|
| Antibodies, Viral | 3 | 2022 | 1121 | 0.180 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 226 | 0.180 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 3 | 2017 | 59 | 0.180 |
Why?
|
| Paraganglioma, Extra-Adrenal | 1 | 2020 | 11 | 0.180 |
Why?
|
| Anticoagulants | 2 | 2022 | 578 | 0.180 |
Why?
|
| Virulence Factors | 3 | 2022 | 170 | 0.180 |
Why?
|
| Blood Glucose | 2 | 2022 | 1103 | 0.180 |
Why?
|
| Heart Ventricles | 2 | 2025 | 766 | 0.180 |
Why?
|
| Paraganglioma | 1 | 2020 | 19 | 0.180 |
Why?
|
| Physical Examination | 1 | 2001 | 162 | 0.180 |
Why?
|
| Education, Distance | 1 | 2021 | 64 | 0.180 |
Why?
|
| Peripheral Arterial Disease | 1 | 2024 | 252 | 0.180 |
Why?
|
| Professional Autonomy | 1 | 2020 | 27 | 0.180 |
Why?
|
| Pneumonia, Pneumococcal | 3 | 2008 | 82 | 0.180 |
Why?
|
| HIV Protease Inhibitors | 1 | 2020 | 53 | 0.180 |
Why?
|
| Diabetic Cardiomyopathies | 1 | 2020 | 15 | 0.180 |
Why?
|
| Kidney Calculi | 1 | 2020 | 39 | 0.180 |
Why?
|
| Catheter Ablation | 1 | 2023 | 226 | 0.180 |
Why?
|
| Public Opinion | 1 | 2020 | 54 | 0.180 |
Why?
|
| Organ Preservation | 1 | 2020 | 36 | 0.180 |
Why?
|
| Interleukin-7 | 2 | 2012 | 43 | 0.180 |
Why?
|
| Natriuretic Peptides | 1 | 2019 | 6 | 0.170 |
Why?
|
| Students | 4 | 2018 | 249 | 0.170 |
Why?
|
| Extracellular Fluid | 1 | 2019 | 12 | 0.170 |
Why?
|
| Histoplasmosis | 1 | 2000 | 45 | 0.170 |
Why?
|
| alpha-Fetoproteins | 1 | 2021 | 136 | 0.170 |
Why?
|
| Deglutition Disorders | 1 | 2021 | 125 | 0.170 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2017 | 212 | 0.170 |
Why?
|
| Plasma | 1 | 2020 | 96 | 0.170 |
Why?
|
| Fluorometry | 1 | 2019 | 26 | 0.170 |
Why?
|
| Pyloromyotomy | 1 | 2019 | 3 | 0.170 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2020 | 42 | 0.170 |
Why?
|
| Colectomy | 2 | 2013 | 75 | 0.170 |
Why?
|
| Prediabetic State | 1 | 2020 | 57 | 0.170 |
Why?
|
| Models, Biological | 2 | 2022 | 1434 | 0.170 |
Why?
|
| Tuberculosis, Laryngeal | 1 | 2019 | 2 | 0.170 |
Why?
|
| Tuberculosis, Oral | 1 | 2019 | 2 | 0.170 |
Why?
|
| Hypertension, Pulmonary | 2 | 2024 | 422 | 0.170 |
Why?
|
| History, 21st Century | 2 | 2018 | 266 | 0.160 |
Why?
|
| Epidemiological Monitoring | 2 | 2018 | 59 | 0.160 |
Why?
|
| Specialties, Surgical | 1 | 2020 | 76 | 0.160 |
Why?
|
| Reagent Kits, Diagnostic | 3 | 2019 | 53 | 0.160 |
Why?
|
| False Positive Reactions | 2 | 2016 | 142 | 0.160 |
Why?
|
| Liver Diseases | 1 | 2023 | 382 | 0.160 |
Why?
|
| Cardiovascular Diseases | 2 | 2021 | 1810 | 0.160 |
Why?
|
| Tricuspid Valve | 1 | 2019 | 61 | 0.160 |
Why?
|
| Teaching | 1 | 2020 | 182 | 0.160 |
Why?
|
| Occupational Health | 1 | 2019 | 44 | 0.160 |
Why?
|
| Constriction, Pathologic | 1 | 2020 | 226 | 0.160 |
Why?
|
| Models, Cardiovascular | 1 | 2020 | 168 | 0.160 |
Why?
|
| Methacholine Chloride | 1 | 2018 | 21 | 0.160 |
Why?
|
| Datasets as Topic | 1 | 2019 | 84 | 0.160 |
Why?
|
| Ciprofloxacin | 1 | 2019 | 66 | 0.160 |
Why?
|
| Attitude to Health | 1 | 2020 | 253 | 0.160 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 175 | 0.160 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 118 | 0.160 |
Why?
|
| War Exposure | 1 | 2018 | 8 | 0.160 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2019 | 85 | 0.160 |
Why?
|
| Streptococcal Infections | 5 | 2008 | 240 | 0.160 |
Why?
|
| Contrast Media | 4 | 2023 | 452 | 0.160 |
Why?
|
| Bronchial Hyperreactivity | 1 | 2018 | 40 | 0.160 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2025 | 3433 | 0.160 |
Why?
|
| Primary Graft Dysfunction | 1 | 2018 | 22 | 0.160 |
Why?
|
| Length of Stay | 6 | 2024 | 1250 | 0.160 |
Why?
|
| Ascaris lumbricoides | 1 | 2018 | 18 | 0.150 |
Why?
|
| Schistosoma haematobium | 1 | 2018 | 18 | 0.150 |
Why?
|
| Methylprednisolone | 1 | 2018 | 91 | 0.150 |
Why?
|
| Blood Flow Velocity | 1 | 2020 | 446 | 0.150 |
Why?
|
| Fluoroquinolones | 3 | 2019 | 98 | 0.150 |
Why?
|
| Health Services | 1 | 2018 | 71 | 0.150 |
Why?
|
| Vitamin D Deficiency | 1 | 2019 | 69 | 0.150 |
Why?
|
| Shock, Cardiogenic | 1 | 2020 | 189 | 0.150 |
Why?
|
| Troponin T | 1 | 2019 | 243 | 0.150 |
Why?
|
| Endothelium, Vascular | 1 | 2021 | 522 | 0.150 |
Why?
|
| Refugees | 1 | 2018 | 31 | 0.150 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2017 | 12 | 0.150 |
Why?
|
| Molecular Sequence Data | 8 | 2014 | 3870 | 0.150 |
Why?
|
| Costs and Cost Analysis | 2 | 2016 | 161 | 0.150 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2019 | 188 | 0.150 |
Why?
|
| Infection Control | 2 | 2016 | 161 | 0.150 |
Why?
|
| Biomarkers | 7 | 2021 | 2922 | 0.150 |
Why?
|
| Schistosomiasis | 1 | 2018 | 49 | 0.150 |
Why?
|
| Ethanol | 1 | 2019 | 160 | 0.150 |
Why?
|
| Gadolinium | 3 | 2023 | 102 | 0.150 |
Why?
|
| Immunotherapy | 1 | 2003 | 655 | 0.150 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2021 | 479 | 0.150 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2018 | 62 | 0.150 |
Why?
|
| Ascariasis | 1 | 2018 | 58 | 0.150 |
Why?
|
| Hyaluronan Receptors | 1 | 2017 | 68 | 0.150 |
Why?
|
| Microscopy | 2 | 2024 | 119 | 0.150 |
Why?
|
| Aptamers, Nucleotide | 1 | 2017 | 24 | 0.150 |
Why?
|
| Communicable Diseases | 1 | 2020 | 163 | 0.150 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2024 | 710 | 0.150 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2017 | 18 | 0.150 |
Why?
|
| Gene Expression Regulation, Bacterial | 5 | 2008 | 153 | 0.140 |
Why?
|
| beta-Lactamases | 1 | 2019 | 195 | 0.140 |
Why?
|
| Faculty, Medical | 1 | 2020 | 262 | 0.140 |
Why?
|
| Th1 Cells | 1 | 2018 | 147 | 0.140 |
Why?
|
| Diabetes Complications | 1 | 2019 | 196 | 0.140 |
Why?
|
| Social Class | 2 | 2019 | 180 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 1115 | 0.140 |
Why?
|
| Gastroesophageal Reflux | 1 | 2020 | 288 | 0.140 |
Why?
|
| Surgical Mesh | 1 | 2017 | 61 | 0.140 |
Why?
|
| Drug Carriers | 1 | 2017 | 97 | 0.140 |
Why?
|
| Pandemics | 2 | 2022 | 1100 | 0.140 |
Why?
|
| Sepsis | 1 | 2021 | 471 | 0.140 |
Why?
|
| Skin Tests | 2 | 2015 | 76 | 0.140 |
Why?
|
| Stomach | 1 | 2019 | 272 | 0.140 |
Why?
|
| Pneumococcal Vaccines | 3 | 2008 | 169 | 0.140 |
Why?
|
| Bradykinin | 1 | 2016 | 57 | 0.140 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 104 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 288 | 0.140 |
Why?
|
| Scleroderma, Systemic | 1 | 2018 | 117 | 0.140 |
Why?
|
| Riboflavin | 1 | 2016 | 37 | 0.140 |
Why?
|
| Immunologic Memory | 1 | 2017 | 180 | 0.140 |
Why?
|
| Schistosoma | 1 | 2016 | 9 | 0.130 |
Why?
|
| Cephalosporins | 2 | 2014 | 137 | 0.130 |
Why?
|
| Forkhead Transcription Factors | 2 | 2010 | 369 | 0.130 |
Why?
|
| Antibodies | 2 | 2016 | 383 | 0.130 |
Why?
|
| Heme Oxygenase-1 | 1 | 2016 | 34 | 0.130 |
Why?
|
| Polymerase Chain Reaction | 6 | 2006 | 1591 | 0.130 |
Why?
|
| Cytomegalovirus Infections | 1 | 2018 | 217 | 0.130 |
Why?
|
| Polysaccharides | 2 | 2007 | 141 | 0.130 |
Why?
|
| Optical Imaging | 1 | 2016 | 65 | 0.130 |
Why?
|
| Mexico | 4 | 2005 | 176 | 0.130 |
Why?
|
| Adhesins, Bacterial | 2 | 2007 | 75 | 0.130 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2018 | 512 | 0.130 |
Why?
|
| Likelihood Functions | 1 | 2016 | 106 | 0.130 |
Why?
|
| Clinical Competence | 4 | 2021 | 970 | 0.130 |
Why?
|
| School Health Services | 1 | 2016 | 98 | 0.130 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2018 | 168 | 0.130 |
Why?
|
| Neurology | 1 | 2017 | 108 | 0.130 |
Why?
|
| Pilot Projects | 4 | 2017 | 1357 | 0.130 |
Why?
|
| Genetic Loci | 1 | 2017 | 334 | 0.130 |
Why?
|
| Dietary Supplements | 1 | 2019 | 457 | 0.130 |
Why?
|
| Patient Care | 1 | 2016 | 98 | 0.130 |
Why?
|
| Nuclear Proteins | 1 | 2002 | 1281 | 0.130 |
Why?
|
| Cooperative Behavior | 1 | 2016 | 215 | 0.120 |
Why?
|
| Antigens, Helminth | 1 | 2016 | 153 | 0.120 |
Why?
|
| Mining | 1 | 2015 | 8 | 0.120 |
Why?
|
| Outpatients | 1 | 2017 | 252 | 0.120 |
Why?
|
| Pharmacy Service, Hospital | 1 | 1995 | 49 | 0.120 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2005 | 313 | 0.120 |
Why?
|
| Animals | 17 | 2024 | 33670 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 359 | 0.120 |
Why?
|
| Head and Neck Neoplasms | 1 | 2019 | 469 | 0.120 |
Why?
|
| Molecular Typing | 2 | 2012 | 33 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 377 | 0.120 |
Why?
|
| Ophthalmology | 1 | 2017 | 194 | 0.120 |
Why?
|
| Immunologic Factors | 1 | 2016 | 176 | 0.120 |
Why?
|
| Health Care Costs | 2 | 2016 | 358 | 0.120 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2022 | 654 | 0.120 |
Why?
|
| Medical Records | 2 | 2013 | 189 | 0.120 |
Why?
|
| Hydrolases | 1 | 2014 | 79 | 0.120 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 1055 | 0.120 |
Why?
|
| Cells, Cultured | 6 | 2019 | 3069 | 0.120 |
Why?
|
| Travel | 2 | 2013 | 117 | 0.120 |
Why?
|
| HIV Seropositivity | 3 | 2017 | 115 | 0.120 |
Why?
|
| Transplantation | 1 | 2014 | 29 | 0.110 |
Why?
|
| Anti-HIV Agents | 3 | 2016 | 304 | 0.110 |
Why?
|
| Nanotechnology | 1 | 2014 | 47 | 0.110 |
Why?
|
| Mycobacterium avium Complex | 2 | 2006 | 22 | 0.110 |
Why?
|
| Enzyme Inhibitors | 1 | 2016 | 581 | 0.110 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 303 | 0.110 |
Why?
|
| Body Mass Index | 4 | 2022 | 1457 | 0.110 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 4 | 2007 | 91 | 0.110 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 1225 | 0.110 |
Why?
|
| Probability | 2 | 2004 | 319 | 0.110 |
Why?
|
| Chaperonins | 3 | 2007 | 16 | 0.110 |
Why?
|
| DNA Fingerprinting | 5 | 2007 | 105 | 0.100 |
Why?
|
| Oligonucleotides | 3 | 2005 | 88 | 0.100 |
Why?
|
| Antibodies, Bacterial | 5 | 2008 | 384 | 0.100 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2021 | 1096 | 0.100 |
Why?
|
| T-Lymphocytes | 4 | 2020 | 1673 | 0.100 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2012 | 35 | 0.100 |
Why?
|
| Evolution, Molecular | 2 | 2013 | 669 | 0.100 |
Why?
|
| Diagnostic Errors | 1 | 2016 | 314 | 0.100 |
Why?
|
| Population Density | 1 | 2011 | 34 | 0.100 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2012 | 43 | 0.100 |
Why?
|
| Endemic Diseases | 1 | 2011 | 56 | 0.100 |
Why?
|
| Transportation | 1 | 2011 | 27 | 0.100 |
Why?
|
| Epidemiologic Methods | 1 | 2011 | 105 | 0.100 |
Why?
|
| DNA Methylation | 1 | 2018 | 988 | 0.100 |
Why?
|
| Tuberculoma, Intracranial | 1 | 2011 | 7 | 0.100 |
Why?
|
| Risk | 3 | 2021 | 743 | 0.100 |
Why?
|
| Proteinuria | 2 | 2022 | 108 | 0.100 |
Why?
|
| Ofloxacin | 1 | 2011 | 32 | 0.100 |
Why?
|
| Surgical Procedures, Operative | 1 | 2013 | 182 | 0.100 |
Why?
|
| Age Distribution | 2 | 2003 | 399 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1248 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 682 | 0.090 |
Why?
|
| Carrier Proteins | 2 | 2007 | 1022 | 0.090 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2022 | 141 | 0.090 |
Why?
|
| DNA Mutational Analysis | 1 | 2013 | 791 | 0.090 |
Why?
|
| Drug Resistance, Microbial | 2 | 2001 | 193 | 0.090 |
Why?
|
| Lighting | 1 | 2010 | 19 | 0.090 |
Why?
|
| Oropharynx | 2 | 2008 | 33 | 0.090 |
Why?
|
| Electric Power Supplies | 1 | 2010 | 16 | 0.090 |
Why?
|
| Pneumonectomy | 2 | 2022 | 140 | 0.090 |
Why?
|
| Preoperative Period | 2 | 2021 | 82 | 0.090 |
Why?
|
| Reference Values | 2 | 2019 | 699 | 0.090 |
Why?
|
| Immunization, Passive | 2 | 2020 | 116 | 0.090 |
Why?
|
| Radiography | 2 | 2018 | 797 | 0.090 |
Why?
|
| GTP-Binding Proteins | 1 | 2011 | 176 | 0.090 |
Why?
|
| Universities | 1 | 2011 | 125 | 0.090 |
Why?
|
| Propensity Score | 2 | 2021 | 198 | 0.090 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 581 | 0.090 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2012 | 220 | 0.080 |
Why?
|
| RNA, Viral | 3 | 2020 | 541 | 0.080 |
Why?
|
| Pharynx | 2 | 2007 | 63 | 0.080 |
Why?
|
| Iran | 1 | 2009 | 63 | 0.080 |
Why?
|
| Hospitals, Veterans | 2 | 2006 | 353 | 0.080 |
Why?
|
| Macrolides | 2 | 2006 | 28 | 0.080 |
Why?
|
| Immunity, Innate | 2 | 2022 | 375 | 0.080 |
Why?
|
| Heart Atria | 2 | 2023 | 308 | 0.080 |
Why?
|
| Longitudinal Studies | 3 | 2020 | 1275 | 0.080 |
Why?
|
| Cytokines | 3 | 2022 | 1274 | 0.080 |
Why?
|
| Mice | 8 | 2024 | 17494 | 0.080 |
Why?
|
| DNA Primers | 3 | 2005 | 667 | 0.080 |
Why?
|
| Viral Load | 4 | 2019 | 381 | 0.080 |
Why?
|
| Early Diagnosis | 1 | 2009 | 178 | 0.080 |
Why?
|
| Coronary Artery Disease | 1 | 2015 | 739 | 0.080 |
Why?
|
| Allografts | 2 | 2020 | 182 | 0.080 |
Why?
|
| Academic Medical Centers | 2 | 2023 | 294 | 0.080 |
Why?
|
| Postoperative Period | 2 | 2020 | 330 | 0.080 |
Why?
|
| Cryptococcus neoformans | 3 | 1998 | 20 | 0.080 |
Why?
|
| Meningococcal Vaccines | 1 | 2008 | 30 | 0.080 |
Why?
|
| Peptides | 2 | 2017 | 799 | 0.080 |
Why?
|
| Bacterial Load | 2 | 2019 | 29 | 0.080 |
Why?
|
| Pharyngitis | 2 | 2005 | 31 | 0.080 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2007 | 368 | 0.080 |
Why?
|
| Chemokine CXCL6 | 1 | 2008 | 16 | 0.080 |
Why?
|
| Chemokine CXCL1 | 1 | 2008 | 18 | 0.080 |
Why?
|
| Vascular Surgical Procedures | 1 | 2013 | 523 | 0.080 |
Why?
|
| Recombinant Proteins | 2 | 2012 | 1368 | 0.080 |
Why?
|
| Wisconsin | 2 | 2004 | 19 | 0.070 |
Why?
|
| Carbohydrate Metabolism | 1 | 2008 | 54 | 0.070 |
Why?
|
| Analysis of Variance | 4 | 2013 | 1004 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 371 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 3 | 2008 | 1357 | 0.070 |
Why?
|
| Toll-Like Receptors | 1 | 2007 | 83 | 0.070 |
Why?
|
| RNA, Ribosomal, 23S | 1 | 2007 | 21 | 0.070 |
Why?
|
| Cryptosporidium | 1 | 2007 | 32 | 0.070 |
Why?
|
| Reoperation | 2 | 2023 | 771 | 0.070 |
Why?
|
| Cell Line | 4 | 2017 | 2787 | 0.070 |
Why?
|
| Anus, Imperforate | 1 | 2007 | 21 | 0.070 |
Why?
|
| Acinetobacter Infections | 1 | 2007 | 26 | 0.070 |
Why?
|
| Phenotype | 2 | 2017 | 4207 | 0.070 |
Why?
|
| Fimbriae, Bacterial | 1 | 2007 | 41 | 0.070 |
Why?
|
| Urban Health | 2 | 2004 | 71 | 0.070 |
Why?
|
| Trisaccharides | 1 | 2007 | 2 | 0.070 |
Why?
|
| Acinetobacter baumannii | 1 | 2007 | 36 | 0.070 |
Why?
|
| Periplasmic Binding Proteins | 1 | 2007 | 36 | 0.070 |
Why?
|
| Schools | 2 | 2018 | 212 | 0.070 |
Why?
|
| Statistics, Nonparametric | 2 | 2011 | 418 | 0.070 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2007 | 40 | 0.070 |
Why?
|
| Insulin | 2 | 2024 | 1190 | 0.070 |
Why?
|
| Peptide Hydrolases | 1 | 2008 | 141 | 0.070 |
Why?
|
| Sentinel Surveillance | 1 | 2006 | 19 | 0.070 |
Why?
|
| Fecal Incontinence | 1 | 2007 | 68 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2020 | 865 | 0.070 |
Why?
|
| Splenic Diseases | 1 | 2006 | 28 | 0.070 |
Why?
|
| Bacterial Adhesion | 1 | 2007 | 108 | 0.070 |
Why?
|
| Splenectomy | 1 | 2006 | 59 | 0.070 |
Why?
|
| Protozoan Proteins | 1 | 2007 | 106 | 0.070 |
Why?
|
| Polysaccharides, Bacterial | 1 | 2006 | 67 | 0.070 |
Why?
|
| Biofilms | 1 | 2007 | 93 | 0.070 |
Why?
|
| Neurosurgical Procedures | 1 | 2009 | 296 | 0.070 |
Why?
|
| Community Health Services | 2 | 2006 | 90 | 0.070 |
Why?
|
| Repressor Proteins | 2 | 2008 | 810 | 0.070 |
Why?
|
| Bacterial Vaccines | 2 | 1997 | 101 | 0.070 |
Why?
|
| Suction | 1 | 2006 | 56 | 0.070 |
Why?
|
| Survival Analysis | 3 | 2021 | 1460 | 0.070 |
Why?
|
| Vaccination | 3 | 2008 | 920 | 0.070 |
Why?
|
| Colonic Diseases | 1 | 2006 | 38 | 0.070 |
Why?
|
| Peroxidases | 2 | 2003 | 26 | 0.070 |
Why?
|
| Apoptosis | 3 | 2020 | 1788 | 0.070 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2007 | 190 | 0.060 |
Why?
|
| Repetitive Sequences, Amino Acid | 1 | 2005 | 19 | 0.060 |
Why?
|
| Autophagy | 2 | 2020 | 391 | 0.060 |
Why?
|
| Lymphocytes | 1 | 2007 | 416 | 0.060 |
Why?
|
| Colony Count, Microbial | 2 | 2018 | 89 | 0.060 |
Why?
|
| Pyrazinamide | 1 | 2005 | 14 | 0.060 |
Why?
|
| Pneumonia, Bacterial | 1 | 2006 | 77 | 0.060 |
Why?
|
| Genetic Variation | 4 | 2005 | 1475 | 0.060 |
Why?
|
| Amidohydrolases | 1 | 2005 | 18 | 0.060 |
Why?
|
| Thiourea | 1 | 2004 | 9 | 0.060 |
Why?
|
| Hospitals, Military | 1 | 2004 | 10 | 0.060 |
Why?
|
| Gene Frequency | 1 | 2007 | 707 | 0.060 |
Why?
|
| Diagnosis, Differential | 3 | 2006 | 1872 | 0.060 |
Why?
|
| Exons | 1 | 2007 | 794 | 0.060 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2005 | 105 | 0.060 |
Why?
|
| Cell Survival | 1 | 2007 | 817 | 0.060 |
Why?
|
| Abscess | 1 | 2006 | 138 | 0.060 |
Why?
|
| Acute Kidney Injury | 1 | 2012 | 598 | 0.060 |
Why?
|
| Sex Characteristics | 2 | 2023 | 301 | 0.060 |
Why?
|
| Mass Spectrometry | 2 | 2017 | 323 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 2 | 2017 | 975 | 0.060 |
Why?
|
| Patient Compliance | 2 | 2006 | 464 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 1295 | 0.060 |
Why?
|
| Proinsulin | 1 | 2024 | 12 | 0.060 |
Why?
|
| Family | 3 | 2018 | 569 | 0.060 |
Why?
|
| Abatacept | 1 | 2024 | 19 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2007 | 445 | 0.060 |
Why?
|
| Methionyl Aminopeptidases | 1 | 2023 | 2 | 0.060 |
Why?
|
| Community-Institutional Relations | 1 | 2024 | 30 | 0.060 |
Why?
|
| Cobalt | 1 | 2023 | 17 | 0.060 |
Why?
|
| Cities | 1 | 2004 | 47 | 0.060 |
Why?
|
| Sampling Studies | 1 | 2004 | 74 | 0.060 |
Why?
|
| Osteocalcin | 1 | 2024 | 41 | 0.060 |
Why?
|
| Proteasome Inhibitors | 1 | 2024 | 62 | 0.060 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2003 | 14 | 0.060 |
Why?
|
| Tuberculosis, Cutaneous | 1 | 2003 | 4 | 0.060 |
Why?
|
| Nickel | 1 | 2023 | 22 | 0.060 |
Why?
|
| Glucagon | 1 | 2024 | 187 | 0.060 |
Why?
|
| Carrier State | 1 | 2004 | 76 | 0.060 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2005 | 169 | 0.060 |
Why?
|
| Lipoproteins, LDL | 1 | 2024 | 114 | 0.060 |
Why?
|
| Disease Progression | 2 | 2020 | 1970 | 0.060 |
Why?
|
| Nuclear Family | 1 | 2003 | 50 | 0.060 |
Why?
|
| Metals | 1 | 2023 | 58 | 0.050 |
Why?
|
| Operon | 1 | 2003 | 52 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2003 | 283 | 0.050 |
Why?
|
| Hypertrophy | 1 | 2023 | 99 | 0.050 |
Why?
|
| Selection Bias | 1 | 2002 | 19 | 0.050 |
Why?
|
| Dinucleotide Repeats | 1 | 2002 | 5 | 0.050 |
Why?
|
| Oxidoreductases | 1 | 2003 | 92 | 0.050 |
Why?
|
| Base Sequence | 5 | 2005 | 3114 | 0.050 |
Why?
|
| Fibroblasts | 1 | 2007 | 874 | 0.050 |
Why?
|
| Equipment Design | 2 | 2017 | 586 | 0.050 |
Why?
|
| Peritonitis | 2 | 2007 | 76 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2024 | 4333 | 0.050 |
Why?
|
| Factor Xa | 1 | 2022 | 17 | 0.050 |
Why?
|
| Desensitization, Immunologic | 1 | 2024 | 95 | 0.050 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2024 | 214 | 0.050 |
Why?
|
| Diastole | 1 | 2023 | 170 | 0.050 |
Why?
|
| Administration, Intranasal | 1 | 2002 | 128 | 0.050 |
Why?
|
| Hepatitis | 1 | 2003 | 65 | 0.050 |
Why?
|
| Hernia, Ventral | 1 | 2002 | 39 | 0.050 |
Why?
|
| Diet, High-Fat | 1 | 2024 | 206 | 0.050 |
Why?
|
| Hemolysis | 1 | 2022 | 103 | 0.050 |
Why?
|
| Community-Acquired Infections | 1 | 2004 | 240 | 0.050 |
Why?
|
| Faecalibacterium | 1 | 2022 | 3 | 0.050 |
Why?
|
| Chaperonin 60 | 3 | 2007 | 32 | 0.050 |
Why?
|
| Glycemic Index | 1 | 2022 | 18 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2004 | 296 | 0.050 |
Why?
|
| Rivaroxaban | 1 | 2022 | 55 | 0.050 |
Why?
|
| Surgical Stapling | 1 | 2022 | 17 | 0.050 |
Why?
|
| Phylogeny | 4 | 2005 | 682 | 0.050 |
Why?
|
| Anastomotic Leak | 1 | 2022 | 28 | 0.050 |
Why?
|
| Fibrinogen | 1 | 2022 | 152 | 0.050 |
Why?
|
| Esophagogastric Junction | 1 | 2021 | 26 | 0.050 |
Why?
|
| Rural Population | 1 | 2003 | 241 | 0.050 |
Why?
|
| Poverty | 3 | 2016 | 410 | 0.050 |
Why?
|
| Renal Artery | 1 | 2021 | 52 | 0.050 |
Why?
|
| Opportunistic Infections | 2 | 2019 | 77 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2021 | 51 | 0.050 |
Why?
|
| Proteins | 1 | 2007 | 1046 | 0.050 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2022 | 112 | 0.050 |
Why?
|
| Immunity, Humoral | 1 | 2022 | 68 | 0.050 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2021 | 99 | 0.050 |
Why?
|
| Postoperative Hemorrhage | 1 | 2022 | 85 | 0.050 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2003 | 190 | 0.050 |
Why?
|
| Gastrectomy | 1 | 2022 | 87 | 0.050 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2002 | 115 | 0.050 |
Why?
|
| Frozen Sections | 1 | 2000 | 24 | 0.050 |
Why?
|
| Fibrinolytic Agents | 1 | 2022 | 199 | 0.050 |
Why?
|
| Organophosphates | 1 | 2020 | 13 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2022 | 302 | 0.050 |
Why?
|
| Georgia | 2 | 2016 | 28 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 4278 | 0.050 |
Why?
|
| Cold Ischemia | 1 | 2020 | 16 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2021 | 263 | 0.050 |
Why?
|
| Blood Component Transfusion | 1 | 2020 | 53 | 0.040 |
Why?
|
| Death | 1 | 2021 | 71 | 0.040 |
Why?
|
| Appendectomy | 1 | 2021 | 88 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2022 | 664 | 0.040 |
Why?
|
| Operative Time | 1 | 2021 | 149 | 0.040 |
Why?
|
| Self-Assessment | 1 | 2020 | 65 | 0.040 |
Why?
|
| Histoplasma | 1 | 2000 | 28 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2020 | 1144 | 0.040 |
Why?
|
| Antigens, CD34 | 1 | 2020 | 106 | 0.040 |
Why?
|
| Medical Futility | 1 | 2020 | 36 | 0.040 |
Why?
|
| Pyrimidinones | 1 | 2020 | 40 | 0.040 |
Why?
|
| Fasting | 1 | 2022 | 298 | 0.040 |
Why?
|
| Biopsy | 1 | 2024 | 1242 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2019 | 999 | 0.040 |
Why?
|
| Vasodilation | 1 | 2021 | 191 | 0.040 |
Why?
|
| Hospitalization | 2 | 2020 | 1719 | 0.040 |
Why?
|
| Azepines | 1 | 2020 | 62 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2020 | 228 | 0.040 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2021 | 286 | 0.040 |
Why?
|
| Aorta | 1 | 2023 | 518 | 0.040 |
Why?
|
| Gene Deletion | 3 | 2008 | 799 | 0.040 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2000 | 62 | 0.040 |
Why?
|
| Alkaline Phosphatase | 1 | 2000 | 96 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2020 | 252 | 0.040 |
Why?
|
| Gadolinium DTPA | 1 | 2019 | 48 | 0.040 |
Why?
|
| Extracellular Space | 1 | 2019 | 89 | 0.040 |
Why?
|
| Nutritional Status | 1 | 2022 | 296 | 0.040 |
Why?
|
| Ablation Techniques | 1 | 2020 | 32 | 0.040 |
Why?
|
| Kidney Diseases | 1 | 2024 | 469 | 0.040 |
Why?
|
| Esophageal Sphincter, Lower | 1 | 2019 | 11 | 0.040 |
Why?
|
| Aortic Valve | 1 | 2023 | 425 | 0.040 |
Why?
|
| Vegetables | 1 | 2022 | 256 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2000 | 249 | 0.040 |
Why?
|
| Collagen | 1 | 2001 | 311 | 0.040 |
Why?
|
| Thrombelastography | 1 | 2020 | 55 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2016 | 814 | 0.040 |
Why?
|
| Triazoles | 1 | 2020 | 138 | 0.040 |
Why?
|
| Perfusion | 1 | 2020 | 192 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2008 | 2036 | 0.040 |
Why?
|
| Homosexuality, Male | 1 | 1999 | 61 | 0.040 |
Why?
|
| Vascular Resistance | 1 | 2020 | 189 | 0.040 |
Why?
|
| Calibration | 1 | 2019 | 82 | 0.040 |
Why?
|
| Adenoma | 1 | 2000 | 133 | 0.040 |
Why?
|
| Dilatation, Pathologic | 1 | 2019 | 89 | 0.040 |
Why?
|
| Pneumonia | 1 | 2003 | 325 | 0.040 |
Why?
|
| Amino Acid Sequence | 3 | 2014 | 2677 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 314 | 0.040 |
Why?
|
| Gene Dosage | 1 | 2001 | 441 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 299 | 0.040 |
Why?
|
| Triglycerides | 1 | 2021 | 556 | 0.040 |
Why?
|
| Overweight | 1 | 2022 | 339 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2020 | 230 | 0.040 |
Why?
|
| Bronchoconstrictor Agents | 1 | 2018 | 11 | 0.040 |
Why?
|
| Pyridines | 1 | 2020 | 222 | 0.040 |
Why?
|
| Cholesterol | 1 | 2021 | 517 | 0.040 |
Why?
|
| Social Support | 1 | 2001 | 341 | 0.040 |
Why?
|
| Family Characteristics | 1 | 2019 | 76 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2021 | 320 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 183 | 0.040 |
Why?
|
| Piperazines | 1 | 2020 | 227 | 0.040 |
Why?
|
| Linear Models | 1 | 2020 | 655 | 0.040 |
Why?
|
| Middle East | 1 | 2018 | 33 | 0.040 |
Why?
|
| Lung Diseases, Fungal | 1 | 1998 | 34 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2020 | 655 | 0.040 |
Why?
|
| Heart | 1 | 2023 | 719 | 0.040 |
Why?
|
| Cerebrovascular Disorders | 1 | 2019 | 115 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 1976 | 0.040 |
Why?
|
| Receptors, Cytokine | 1 | 2018 | 57 | 0.040 |
Why?
|
| Carcinoma | 1 | 2000 | 282 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2018 | 59 | 0.040 |
Why?
|
| Organ Size | 1 | 2019 | 411 | 0.040 |
Why?
|
| Mycophenolic Acid | 1 | 2018 | 50 | 0.040 |
Why?
|
| Pulmonary Artery | 1 | 2021 | 437 | 0.040 |
Why?
|
| Interleukin-4 | 1 | 2018 | 140 | 0.040 |
Why?
|
| Silicon | 1 | 2017 | 12 | 0.040 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2003 | 541 | 0.040 |
Why?
|
| Protein Biosynthesis | 1 | 2001 | 669 | 0.040 |
Why?
|
| Social Determinants of Health | 1 | 2019 | 110 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 726 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2019 | 173 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2019 | 755 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 608 | 0.040 |
Why?
|
| Phagocytosis | 2 | 2008 | 175 | 0.040 |
Why?
|
| Glucose | 1 | 2022 | 876 | 0.040 |
Why?
|
| California | 1 | 2017 | 122 | 0.040 |
Why?
|
| Isocoumarins | 1 | 2016 | 2 | 0.040 |
Why?
|
| Maryland | 1 | 2016 | 28 | 0.030 |
Why?
|
| Culture Media | 2 | 2008 | 183 | 0.030 |
Why?
|
| Saliva | 2 | 2008 | 114 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2017 | 188 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2019 | 252 | 0.030 |
Why?
|
| RNA, Bacterial | 2 | 2007 | 53 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2020 | 447 | 0.030 |
Why?
|
| Cryptosporidiosis | 1 | 1997 | 40 | 0.030 |
Why?
|
| Nanomedicine | 1 | 2016 | 12 | 0.030 |
Why?
|
| Global Health | 1 | 2021 | 554 | 0.030 |
Why?
|
| Coumarins | 1 | 2016 | 23 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 2018 | 268 | 0.030 |
Why?
|
| Students, Medical | 1 | 2021 | 357 | 0.030 |
Why?
|
| Massachusetts | 1 | 2016 | 124 | 0.030 |
Why?
|
| Microbial Viability | 1 | 2016 | 41 | 0.030 |
Why?
|
| Directly Observed Therapy | 1 | 2016 | 24 | 0.030 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 1996 | 8 | 0.030 |
Why?
|
| U937 Cells | 1 | 2016 | 26 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2024 | 779 | 0.030 |
Why?
|
| Phagosomes | 1 | 2016 | 34 | 0.030 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2016 | 41 | 0.030 |
Why?
|
| Bacterial Capsules | 1 | 1996 | 37 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2024 | 3762 | 0.030 |
Why?
|
| Smoking | 1 | 2021 | 1027 | 0.030 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2020 | 423 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2016 | 96 | 0.030 |
Why?
|
| Genetic Markers | 2 | 2011 | 597 | 0.030 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 1996 | 41 | 0.030 |
Why?
|
| Remission Induction | 1 | 2016 | 299 | 0.030 |
Why?
|
| Hospital Bed Capacity, 500 and over | 1 | 1995 | 15 | 0.030 |
Why?
|
| Mycoses | 1 | 1997 | 116 | 0.030 |
Why?
|
| Papillomavirus Infections | 1 | 2019 | 271 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2018 | 429 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2016 | 263 | 0.030 |
Why?
|
| Multidetector Computed Tomography | 1 | 2015 | 31 | 0.030 |
Why?
|
| Codon | 2 | 2005 | 97 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2022 | 2826 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2016 | 148 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2016 | 334 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1997 | 235 | 0.030 |
Why?
|
| Polycystic Kidney Diseases | 1 | 2015 | 33 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2019 | 1564 | 0.030 |
Why?
|
| Curriculum | 1 | 2020 | 713 | 0.030 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 1995 | 62 | 0.030 |
Why?
|
| Diet | 1 | 2022 | 1099 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2017 | 398 | 0.030 |
Why?
|
| Vascular Calcification | 1 | 2015 | 47 | 0.030 |
Why?
|
| Catheter-Related Infections | 1 | 2016 | 129 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 1996 | 192 | 0.030 |
Why?
|
| South Africa | 1 | 2015 | 98 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 327 | 0.030 |
Why?
|
| Pharmacists | 1 | 1995 | 83 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 487 | 0.030 |
Why?
|
| Gold | 1 | 2015 | 49 | 0.030 |
Why?
|
| Botswana | 1 | 2014 | 76 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 511 | 0.030 |
Why?
|
| Nanoparticles | 1 | 2017 | 227 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2017 | 438 | 0.030 |
Why?
|
| Photoelectron Spectroscopy | 1 | 2014 | 4 | 0.030 |
Why?
|
| Lysosomes | 1 | 2016 | 231 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 1995 | 155 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2015 | 202 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2016 | 700 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 1996 | 292 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 473 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 864 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2014 | 285 | 0.030 |
Why?
|
| Hospitals, Teaching | 2 | 2007 | 103 | 0.030 |
Why?
|
| Streptococcus pneumoniae | 1 | 1996 | 371 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1680 | 0.030 |
Why?
|
| Daptomycin | 1 | 2012 | 13 | 0.030 |
Why?
|
| Bacterial Infections | 1 | 1995 | 303 | 0.030 |
Why?
|
| Liver | 1 | 2020 | 1850 | 0.030 |
Why?
|
| Aminoglycosides | 1 | 2012 | 44 | 0.030 |
Why?
|
| Genome, Human | 1 | 2019 | 1251 | 0.030 |
Why?
|
| Dialysis | 1 | 2012 | 20 | 0.030 |
Why?
|
| Lenses | 1 | 2011 | 5 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2012 | 143 | 0.020 |
Why?
|
| Miniaturization | 1 | 2011 | 27 | 0.020 |
Why?
|
| Transcription Factors | 2 | 2018 | 2586 | 0.020 |
Why?
|
| RNA Stability | 1 | 2012 | 85 | 0.020 |
Why?
|
| Urea | 1 | 2012 | 210 | 0.020 |
Why?
|
| Genomics | 1 | 2019 | 1473 | 0.020 |
Why?
|
| Cerebrospinal Fluid | 1 | 2011 | 92 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 142 | 0.020 |
Why?
|
| CD4 Antigens | 1 | 2010 | 56 | 0.020 |
Why?
|
| Hematologic Tests | 1 | 2010 | 34 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2018 | 2309 | 0.020 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2010 | 43 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 1145 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 1679 | 0.020 |
Why?
|
| Vancomycin | 1 | 2012 | 216 | 0.020 |
Why?
|
| Transcription, Genetic | 2 | 2008 | 1698 | 0.020 |
Why?
|
| Creatinine | 1 | 2012 | 376 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2010 | 275 | 0.020 |
Why?
|
| Lung | 1 | 2017 | 1471 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2017 | 4504 | 0.020 |
Why?
|
| Demography | 2 | 2001 | 238 | 0.020 |
Why?
|
| Antiparasitic Agents | 1 | 2009 | 31 | 0.020 |
Why?
|
| Chromosome Mapping | 2 | 2005 | 1068 | 0.020 |
Why?
|
| Inflammation | 1 | 2016 | 1393 | 0.020 |
Why?
|
| Aging | 1 | 1996 | 1157 | 0.020 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2008 | 25 | 0.020 |
Why?
|
| HIV Core Protein p24 | 1 | 2008 | 13 | 0.020 |
Why?
|
| Sex Factors | 2 | 2003 | 1226 | 0.020 |
Why?
|
| Streptolysins | 1 | 2008 | 10 | 0.020 |
Why?
|
| Neutrophil Activation | 1 | 2008 | 16 | 0.020 |
Why?
|
| Cell Wall | 1 | 2008 | 34 | 0.020 |
Why?
|
| Receptor, IGF Type 2 | 1 | 2007 | 8 | 0.020 |
Why?
|
| Acute Disease | 2 | 2003 | 1085 | 0.020 |
Why?
|
| Lysosomal-Associated Membrane Protein 1 | 1 | 2007 | 10 | 0.020 |
Why?
|
| Salmonella | 1 | 2007 | 28 | 0.020 |
Why?
|
| Enuresis | 1 | 2007 | 6 | 0.020 |
Why?
|
| Crohn Disease | 1 | 2011 | 281 | 0.020 |
Why?
|
| Social Change | 1 | 2007 | 15 | 0.020 |
Why?
|
| Turkey | 1 | 2007 | 57 | 0.020 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2007 | 27 | 0.020 |
Why?
|
| Aminoacyltransferases | 1 | 2007 | 7 | 0.020 |
Why?
|
| Endosomes | 1 | 2007 | 67 | 0.020 |
Why?
|
| Genetic Complementation Test | 1 | 2007 | 89 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2007 | 316 | 0.020 |
Why?
|
| Maltose | 1 | 2007 | 16 | 0.020 |
Why?
|
| Calorimetry | 1 | 2007 | 56 | 0.020 |
Why?
|
| Michigan | 1 | 2006 | 39 | 0.020 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2007 | 87 | 0.020 |
Why?
|
| Multigene Family | 1 | 2007 | 299 | 0.020 |
Why?
|
| Cysteine Endopeptidases | 1 | 2007 | 114 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2009 | 278 | 0.020 |
Why?
|
| Oligosaccharides | 1 | 2007 | 72 | 0.020 |
Why?
|
| North Carolina | 1 | 2006 | 54 | 0.020 |
Why?
|
| Epithelium | 1 | 2007 | 371 | 0.020 |
Why?
|
| Self Concept | 1 | 2007 | 156 | 0.020 |
Why?
|
| Hematologic Diseases | 1 | 2006 | 74 | 0.020 |
Why?
|
| Animal Husbandry | 1 | 2005 | 10 | 0.020 |
Why?
|
| Central America | 1 | 2005 | 20 | 0.020 |
Why?
|
| Clarithromycin | 1 | 2006 | 123 | 0.020 |
Why?
|
| Prophages | 1 | 2005 | 6 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2007 | 348 | 0.020 |
Why?
|
| Laparotomy | 1 | 2006 | 135 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2006 | 111 | 0.020 |
Why?
|
| Neutrophils | 1 | 2008 | 382 | 0.020 |
Why?
|
| Aspartic Acid | 1 | 2005 | 75 | 0.020 |
Why?
|
| Buffers | 1 | 2004 | 32 | 0.020 |
Why?
|
| Kinetics | 1 | 2007 | 1317 | 0.020 |
Why?
|
| Catheterization | 1 | 2006 | 235 | 0.010 |
Why?
|
| Europe | 1 | 2005 | 366 | 0.010 |
Why?
|
| Serine | 1 | 2005 | 174 | 0.010 |
Why?
|
| Genetics, Population | 1 | 2005 | 183 | 0.010 |
Why?
|
| Environmental Monitoring | 1 | 2004 | 63 | 0.010 |
Why?
|
| Indians, North American | 1 | 2004 | 58 | 0.010 |
Why?
|
| Serotyping | 1 | 2004 | 179 | 0.010 |
Why?
|
| Mexican Americans | 1 | 2005 | 197 | 0.010 |
Why?
|
| Geography | 1 | 2004 | 112 | 0.010 |
Why?
|
| Protein Binding | 1 | 2008 | 1734 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2006 | 266 | 0.010 |
Why?
|
| Brazil | 1 | 2003 | 117 | 0.010 |
Why?
|
| Lymphoma | 1 | 2006 | 324 | 0.010 |
Why?
|
| Leukemia | 1 | 2006 | 377 | 0.010 |
Why?
|
| Macaca fascicularis | 1 | 2003 | 85 | 0.010 |
Why?
|
| Treatment Refusal | 1 | 2003 | 75 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2007 | 898 | 0.010 |
Why?
|
| HIV | 1 | 2003 | 179 | 0.010 |
Why?
|
| Swine | 1 | 2005 | 1157 | 0.010 |
Why?
|
| Caregivers | 1 | 2007 | 560 | 0.010 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2006 | 408 | 0.010 |
Why?
|
| Species Specificity | 1 | 2002 | 550 | 0.010 |
Why?
|
| Genome, Bacterial | 1 | 2002 | 184 | 0.010 |
Why?
|
| Minority Groups | 1 | 2003 | 250 | 0.010 |
Why?
|
| Databases, Genetic | 1 | 2003 | 469 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2008 | 1674 | 0.010 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2000 | 22 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 654 | 0.010 |
Why?
|
| Heterosexuality | 1 | 1999 | 10 | 0.010 |
Why?
|
| Bisexuality | 1 | 1999 | 15 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2001 | 728 | 0.010 |
Why?
|
| Brain | 1 | 2011 | 2944 | 0.010 |
Why?
|
| San Francisco | 1 | 1999 | 17 | 0.010 |
Why?
|
| Interpersonal Relations | 1 | 2001 | 229 | 0.010 |
Why?
|
| Risk-Taking | 1 | 1999 | 93 | 0.010 |
Why?
|
| Hospitals, University | 1 | 1998 | 95 | 0.010 |
Why?
|
| Quality of Life | 1 | 2007 | 1897 | 0.010 |
Why?
|
| Immunoglobulin Allotypes | 1 | 1997 | 6 | 0.010 |
Why?
|
| Cholecystitis | 1 | 1997 | 20 | 0.010 |
Why?
|
| Jews | 1 | 1997 | 31 | 0.010 |
Why?
|
| Electrophoresis | 1 | 1996 | 46 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 1997 | 146 | 0.010 |
Why?
|
| Random Amplified Polymorphic DNA Technique | 1 | 1996 | 6 | 0.010 |
Why?
|
| Cholangitis, Sclerosing | 1 | 1997 | 54 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1997 | 271 | 0.010 |
Why?
|
| Karyotyping | 1 | 1996 | 337 | 0.010 |
Why?
|
| Enzymes | 1 | 1996 | 51 | 0.010 |
Why?
|
| DNA, Fungal | 1 | 1996 | 75 | 0.010 |
Why?
|
| Gene Amplification | 1 | 1996 | 228 | 0.010 |
Why?
|
| Seasons | 1 | 1997 | 297 | 0.010 |
Why?
|
| Pedigree | 1 | 1997 | 1575 | 0.010 |
Why?
|